Effect of Montelukast Sodium Combined with Salmeterol Xinafoate in Patients with Asthma
Objective:To investigate the therapeutic effect of Montelukast Sodium combined with Salmeterol Xinafoate in patients with asthma.Methods:A total of 100 patients with asthma admitted to Jinan Third People's Hospital from August 2021 to March 2024 were selected as the study objects and were divided into a control group and a study group by random number table method,with 50 cases in each group.The control group was treated with Salmeterol Xinafoate,while the study group was treated with Montelukast Sodium combined with Salmeterol Xinafoate.The levels of inflammatory factors,lung function and occurrence of adverse reactions were compared between the two groups.Results:After treatment,the levels of interleukin-6,interleukin-8 and tumor necrosis factor-α in the study group were lower than those in the control group,the differences were statistically significant(P＜0.05).After treatment,forced expiratory volume in one second(FEV1),forced vital capacity(FVC)and FEV1/FVC in the study group were higher than those in the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the study group was 16.00%,slightly higher than 12.00%in the control group,but there was no statistical significance between the two groups(P＞0.05).Conclusion:Montelukast Sodium combined with Salmeterol Xinafoate can effectively reduce the level of serum inflammatory factors and improve lung function in patients with asthma,it is relatively safe and has high clinical application value.
AsthmaMontelukast SodiumSalmeterol XinafoateInflammatory factorLung function
万方数据
维普
